NeXT Dx™ Test
The Personalis NeXT Dx™ Test* is a comprehensive genomic testing solution that enables oncologists to identify potential therapies and clinical trial options for cancer patients. The NeXT Dx Test is one of the first cancer diagnostic test to profile ~20,000 cancer related genes in both tumor exome and transcriptome. The clinical report documents the genetic alterations found in 248 clinically-relevant, cancer genes, as well as research data that can provide insights into emerging immunotherapy composite biomarkers of medical importance. Single nucleotide variants (SNVs), insertions/deletions (indels), copy number alterations (CNAs), and gene fusions for targeted therapy selection, as well as tumor mutational burden (TMB) and microsatellite instability (MSI) status, are reported for immunotherapy selection.
Next Generation Cancer Care: Results Unique to Your Patient
Personalis provides clinicians with clinically-focused cancer test results that maximize the chance of identifying an approved therapy or trial for each patient as well as information that can support identification of new, advanced biomarkers. These results are unique to the patient’s tumor, cover cancer genes known to be relevant in solid tumors, and provide more potential treatment options than other limited tests.
- Improved detection of alterations in difficult-to-sequence regions of clinically important genes via proprietary methods.
- Analysis of DNA and RNA from the same sample to enable robust identification of gene fusions.
- Integration of immunotherapy-related biomarkers such as MSI and exome-wide TMB.
- Determination of TMB by utilizing the gold-standard, exome-wide analysis of non-synonymous somatic mutations (SNVs and indels).
The NeXT Dx Test report delivers clinically important genomic alterations based on a comprehensive and dynamic variant classification and curation process involving multiple genetic information sources. Our database of potentially relevant therapies and clinical trial matches is continually updated based on the latest scientific and medical evidence.
*Currently only available in the United States.
READY TO ACCELERATE YOUR IMMUNO-ONCOLOGY STRATEGY?